• Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companies
• Provides an insight into the prominent technology types in the expansive drug delivery segment
• Benchmarks the sales performance of the leading prescription pharmaceutical companies in terms of drug delivery

• Assess the ways in which drug delivery technology to add value to pharmaceutical products
• Determine current R&D trends in the drug delivery segment
• Examine the long-term sales performance of each delivery type across the leading prescription pharmaceutical players

Browse the complete Report on Apical Pharmaceutical Pty. Ltd.-Detailed Product Pipeline

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and numbers of products in development by clinical phase.

Original Source:     Apical Market

Buy Now: Market Research Reports

• Coverage of numerous information sources for a comprehensive and up-to-date overview of the subject.
• Evaluation of the opportunities and challenges presented by the 7 major emerging markets as well as Other Asia-Pacific, Latin America, Central and Eastern Europe and Middle East and Africa markets.
• Coverage of market profiles by country and region, including market and epidemiological data
• Coverage of emerging market growth goals, strategies and alliance activity by leading companies
• Extensive analysis of recent government plans for healthcare reform and expanded access in China

• Identify key Emerging Markets with growth potential for Pharmaceuticals, Generics, vaccines, OTC’s, Hepatitis and HIV/AIDS agents, Biosimilars and 3rd World Vaccines and medicines.
• Learn why China is the key growth opportunity for most companies and the expected pharmaceutical industry impact of the current government plans to expand healthcare insurance and access.
• Understand the unmet medical needs and growth drivers for the major Emerging markets.
• Understand the rationale behind numerous recent industry acquisitions and alliances targeting these markets.
• Identify pharmaceutical and generic companies seeking alliances related to these markets.
• Learn 10 key recommendations for success in these markets, based on experience of industry leaders to date.

• Pharmaceutical, biotech and generic companies are targeting the Emerging markets for growth due to declining R+D productivity, significant pending patent expirations and increasing healthcare cost containment measures in the developed markets.
• Opportunities for patented, premium-priced pharmaceuticals, Generics, Biosimilars, Vaccines, OTC’s, Hepatitis and HIV/AIDS agents vary by market.
• The Emerging market opportunities include large population sizes, unmet medical needs, growing economies and increasing public and private healthcare expenditures.
• The challenges encountered in these markets are also numerous and include diverse languages and cultures, healthcare regulations, distribution challenges, preferential treatment for domestic companies and healthcare cost containment measures.

• The vast opportunities for Pharmaceuticals in China appear more attainable than ever given the government’s funding of major Healthcare Reforms to increase healthcare access, infrastructure and services between 2009 and 2011. These healthcare reforms aimed at expanding medical insurance and access while decreasing costs are expected to increase pharmaceutical volume at reduced prices.
• India, with its population of 1.1 billion, high levels of poverty and unmet medical needs and low healthcare expenditures continues to present challenges for the global industry. Opportunities include manufacturing skills including Biosimilar manufacturing. However, the lack of Intellectual Property recognition for several biologics, that prompted Novartis’s shift of R+D investment from India to China, is a concern for the innovative industry.
• The large market shares of generics in the Emerging markets have resulted in numerous generic supply deals by companies including Pfizer, GSK, Sanofi Aventis, Novartis, Daiichi Sankyo and Abbott. Other companies that are seeking generic portfolios through alliances or acquisitions include Astra Zeneca, Lilly, J&J and Merck.
• Mylan and Teva appear to be potential alliance partners for companies seeking generics, based on their product portfolios and limited Emerging Market presence.

• What are the pharmaceutical market sizes, growth forecasts and unmet medical needs in the Emerging markets?
• Is there one definitive list of Emerging markets for Pharmaceuticals?
• What are the opportunities and challenges presented by the major Emerging Market countries and regions?
• How can companies evaluate which Emerging markets offer the greatest opportunities for their growth?
• What are the expectations for the industry impact of the Chinese government’s comprehensive plan for Healthcare reform and expansion?
• Which companies are current industry leaders in terms of Emerging market sales?

• Macroeconomic environment in Australia includes the demographic trends, economic landscape, disease burden and healthcare spending
• Australian healthcare system involving the pharmaceutical spending, intellectual property regime, pricing and reimbursement, healthcare reforms, and recent development in the healthcare sector
• Overview of the Australian pharmaceutical market covering comparative dynamics of major pharmaceutical market, key recent events, therapeutic area analysis, leading product dynamics, generic drug market and the overall market forecast through 2015
• Forecasts and analysis of the leading products in the Australian pharmaceutical market over the period 2009–15 spread across major indications and classes of treatments

• Develop insights for the Australian pharmaceutical market, pricing & regulation, healthcare system and detailed epidemiological status of the common indications/risk factors in the country
• Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Australian market
• Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Australian pharmaceutical market
• Compare the franchises of leading pharmaceutical players across major indications, and understand how market share of leading companies will change in the next 6 years

• The Australian economy grew by 1.5% during the first three quarters of 2009: In 2009, a fiscal stimulus package of over $50bn was introduced to reduce the effect of slowing world economy by the Executive Government of Australia under prime ministership of Kevin Rudd. Increasing demand for commodities from China along with the policy reforms done by the government has helped Australian economy regain buoyancy after just one quarter of decline in growth. The Australian economy grew by 1.5% during the first three quarters of 2009, which was the best performance in OECD (Organization for Economic Co-operation and Development).
• New PBS reforms, insulates certain drugs from reference pricing: Recent changes in the pricing policy shows a shift towards rewarding innovation. Since August 2007, the PBS has been divided into two formularies F1 and F2. F2 drugs will have the price cuts whereas F1 drugs are insulated from reference pricing, even if the mechanism of action of a F1 dug is similar to that in F2. F1 drugs which do not have bioequivalent brands can maintain higher prices according to the new formularies.
• Australian government approved 45% refundable tax credit for R&D companies: Biotechnology research in Australia continues to receive funding from both federal and state governments in Australia (New Zealand trade and enterprise report, January 2009). Apart from the Australian government’s Innovation Investment Follow-on Fund (IIFF, a venture capital fund) in May 2009, the government approved the 45% refundable tax credit for R&D, applicable for companies with a turnover of under $16.7m (Australian dollar, (AUD) 20m). Moreover, IIFF is targeted to address the lack of capital available to the most promising and innovative companies.

• According to 2008 AIHW (Australian Institute of Health and Welfare) report, high life expectancy (second only to Japan) and an increasingly aged population has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. Approximately one in every five adult Australians (nearly 4m people) has some or the other disability and more than 1m people need assistance with their daily activities.
• The Australian pharmaceutical market was valued at around $9bn in 2009 and includes both domestic manufacturers and large pharmaceutical companies, with the latter having a direct base in the country through R&D and marketing. Among foreign players, Pfizer, AstraZeneca, Sanofi-Aventis and Novartis dominated the Australian pharmaceutical market in 2009.
• Cardiovascular disorders, led by Lipitor (Pfizer) and Crestor (AstraZeneca) remained the major therapeutic area in the Australian pharmaceutical market. Cholesterol and triglyceride regulating preparations, angiotensin II inhibitors, ACE inhibitors (plain), were the leading drug classes in the cardiovascular therapy in 2009.
• CNS disorders, led by Zyprexa (Eli Lilly) remained the other leading therapy area in the Australian pharmaceutical market. Antipsychotics, anti-depressants, and mood stabilizers were the major drug classes in this therapy area registering over $250m sales each in 2009.

• What will be the major growth indications and the accompanying growth drivers in the Australian pharmaceutical industry over the next 6 years?
• Which were the leading players in the Australian pharmaceutical market (both multinational and domestic) in 2009?
• Which products will be the future growth drivers for the Australian pharmaceutical market?
• Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?
• How is the competitive landscape of key therapeutic areas in Australia?

Browse the complete Report on: Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets, The

Browse All Kalorama Information Reports at Kalorama Information

At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S. health care system, in response to a variety of factors including continually rising costs of care and declining quality of life.

A Comprehensive Look at the 'Wellness' Industry

Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers. This report looks at the emerging wellness industry and estimates the market for wellness related products and services. This portion of the report examines:

• Drivers of Wellness Services
• Utilization Statistics
• Major Companies and Offerings
• Current Wellness Program Market Size
• Innovative Approaches
• Results of Programs
• General Trends(Weak U.S. Economy, Postponing of Retirement, EMR, Rising Interest in Anti-Aging)
• Industry Trends(Internet-Based Wellness Programs, Usage of Financial Incentives, Emergence of Retail Clinics)

• Allergy Medicines
• Cholesterol Reducers
• Diabetes Drugs
• Gastrointestinal Medications/Proton Pump Inhibitors
• Hypertension Medicines
• Over-the-Counter (OTC) Medicines
• Influenza Vaccines
• Cervical Cancer Vaccines
• Diagnostic Tests
• Cardiovascular, Gastric Banding, and other Devices
• Surgeries,
• Imaging
• Other Medical Services

• Aetna
• Azente Wellness
• Cigna
• Coleman Wellness Solutions
• ConnectiCare
• Corporate Wellness
• ConvergenceHealth
• CuraLinc Healthcare
• Dynamic Wellness
• Employee Health Management Systems
• Hawaii Medical Assurance Association
• incentaHEALTH
• KC Wellness
• Kersh Risk Management.
• Kronos Optimal Health Company
• Mayo Clinic Health Solutions
• MedHealth Solutions
• MO Healthnet
• Multicare Health System
• National Corporate Wellness.
• Nuvita
• PATH
• Physicians Medical Group of Santa Cruz County
• Preventure
• Professional Health Services
• Pure Wellness
• Summit Health..
• San Francisco Wellness Initiative
• US Corporate Wellness
• Wellness Advantage
• Wellness Corporate Solutions
• Wellness Works
• Wyoming State Wellness Program

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

http://reportsandreports.blogspot.com/ 

http://reportsandreports.proarticles.co.uk/ 

http://reportsnreports.wordpress.com/

• A single reference for comparing details on employment protection regulations in different countries, and for the US highlights of major differences in specific states with large pharma employment
• Comprehensive coverage of the changes occurring in pharmaceutical industry employment in developed nations.
• Demonstration of how to achieve a cost-effective workforce reduction while maintaining R&D innovation and manufacturing quality.
• Case studies of issues resulting from workforce reductions and outsourcing of manufacturing and R&D, with numerous examples of pitfalls and best practice.

• Identify current and future trends in pharmaceutical industry employment and understand their causes.
• Assess inter-country (and within the US inter-state) differences in employment protection regulations.
• Gain insight into strategies that have been used for facility divestitures to achieve optimum returns.
• Appreciate the benefits of engaging with key local stakeholders during workforce reductions and site closures, and understand the sanctions which local governments may attempt to impose.
• Understand the important role of employee morale and identify measures to retain key staff.

• From 1996–2005, US pharma’s sales force nearly doubled to 100,000 to support a 26% increase in practicing physicians. However, a significant number of drugs will lose patent protection over the next four years, 2010–2014, representing roughly $60bn in total, and the generic share of the drug market has increased from 49% to 74% of total sales in the US from 2000–2009.
• Different companies are adopting various approaches for R&D outsourcing; for example, Eli Lilly plans to outsource 50%, whereas Novartis is committed to a large internal R&D team.
• In 2007, global big pharma including AZ, Pfizer, GSK, and BMS, first announced its plans to outsource API manufacturing to China and India; in the same year, of the 1,154 generic drug applications to the US FDA, only 13% of the manufacturing plants were in the US, while 43% and 39% of the plants were abroad in China and India respectively.
• Discovery R&D scientific jobs in the pharmaceutical industry require significant years of education and on the job training; in particular, the shift of chemistry jobs overseas will have long-term negative effects on the US pool of chemistry talent that will be difficult to reverse.
• Regional stakeholders, including local business and government leaders, are keenly interested in identifying solutions for the future of manufacturing sites and supplying assistance for the displaced employees.

• The projected growth from 2008–2018 for US pharmaceutical and medicine manufacturing employment lags behind the projected employment growth for all US industries, at 6% versus 11% respectively, due to generic competition and drug production moving overseas.
• OECD synthetic indicators measure the strictness of overall employment protection against dismissals of part- and full-time employees and restrictions on temporary hires, and are low for the US, Canada, and the UK; intermediate for Ireland, Japan, and Hungary; and high for Germany, China, India, and France.
• Companies that work closely with regional stakeholders will gain partners who assist with marketing and locating financial investment and potential buyers for the closed facility.
• The timing of workforce reduction announcements can be crucial to the reception both within the workforce and in the wider community. In some cases, poorly chosen timing has significantly complicated the layoff process and has generated considerable bad press.

• What are the employment protection regulations regarding a mass layoff or facility closure in key states in the US and countries in Europe and Asia?
• What happens to the government tax benefits and incentives when a company undergoes employment reduction?
• When and why do companies provide additional severance and displacement support?
• What two factors are key for a cost-efficient workforce reduction?
• How does a company most effectively and quickly recover from a workforce reduction?
• What is necessary to maintain an innovative R&D group after a workforce reduction?
• What are the long-term risks of outsourcing to China and India? How does a company minimize risk exposure to nonmarket economies?